Janus kinase (JAK) inhibitors are used to stop signaling pathways and growth factors in myelofibrosis. They also provide symptom improvement and spleen volume reduction in patients with myelofibrosis. At the 65th Annual American Society of Hematology (ASH) conference in 2023, Dr. Naveen Pemmaraju, MD, of the University of Texas MD Anderson Cancer Center in Houston, discussed an abstract that utilized a JAK inhibitor combined with navitoclax, a BCL-2 inhibitor that showed successful results.
TRANSFORM-1 is an ongoing, phase 3 study designed to see if a combination of navitoclax and ruxolitinib was more effective and safe in the assessment of change in spleen volume when compared to ruxolitinib alone in participants with myelofibrosis.
Results published from this trial in 2022 showed that the addition of navitoclax to ruxolitinib induced a 35% or greater reduction in spleen volume and reduced symptoms in patients with myelofibrosis no longer benefiting from ruxolitinib.
Patients who were in the group receiving navitoclax + ruxolitinib:
“There remains a substantial unmet need for therapies that alter disease trajectory, improve outcomes, and enhance survival.” These two trials offer effective and important data for the ongoing treatment of myelofibrosis. Additional evaluation fo the phase 3 TRANSFORM trial is ongoig.
Janus kinase (JAK) inhibitors are used to stop signaling pathways and growth factors in myelofibrosis. They also provide symptom improvement and spleen volume reduction in patients with myelofibrosis. At the 65th Annual American Society of Hematology (ASH) conference in 2023, Dr. Naveen Pemmaraju, MD, of the University of Texas MD Anderson Cancer Center in Houston, discussed an abstract that utilized a JAK inhibitor combined with navitoclax, a BCL-2 inhibitor that showed successful results.
TRANSFORM-1 is an ongoing, phase 3 study designed to see if a combination of navitoclax and ruxolitinib was more effective and safe in the assessment of change in spleen volume when compared to ruxolitinib alone in participants with myelofibrosis.
Results published from this trial in 2022 showed that the addition of navitoclax to ruxolitinib induced a 35% or greater reduction in spleen volume and reduced symptoms in patients with myelofibrosis no longer benefiting from ruxolitinib.
Patients who were in the group receiving navitoclax + ruxolitinib:
“There remains a substantial unmet need for therapies that alter disease trajectory, improve outcomes, and enhance survival.” These two trials offer effective and important data for the ongoing treatment of myelofibrosis. Additional evaluation fo the phase 3 TRANSFORM trial is ongoig.
about the author
Lisa Foster
Lisa Foster is a mom of 3 daughters, a puzzle lover, writer and HealthTree advocate. She believes in the mission of the foundation and the team that builds it forward. She calls Houston, Texas home.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.